Wednesday, October 25, 2023 11:12:38 PM
exwannabe,
The science is not completely hidden but was and still is very, very well protected. There are specific things in maturation and activation that are discussed in the patents but are almost never discussed in the general language about activation/maturation. There are specific end product cell characteristics with cytokine and chemokine production that are different than what other DCs produce because of this. This is all about creating DCs that have optimized signaling through activation that is different, maturity that is different and purity that is better that what others produce. Those little tweaks you speak of are very important. Some tweaks, like the amount of time and activators used to create mature DCs that produce certain levels of TNFalpha, IL 12 and other markers of proper activation are known about generally but not the actual exact time or the exact activators other than IL-2 and CSF-1 which is protected though described in the patents and are within the list of potential activators. So you see that the science actually does matter because the recipe matters and the recipe has a right to be protected to a certain extent. Do you know the exact O2 and CO2 levels for cell differentiation and maturation or exact process for creating strongly polarized down to non polar sites on receptors or ligands? It’s all in the tweaks and NWBO has been tweaking while the world was learning about twerking. Big difference; ). Care to tell me all about what NWBO knows about macrophages that makes their platform the one to try to compete against?; ). Best wishes.
The science is not completely hidden but was and still is very, very well protected. There are specific things in maturation and activation that are discussed in the patents but are almost never discussed in the general language about activation/maturation. There are specific end product cell characteristics with cytokine and chemokine production that are different than what other DCs produce because of this. This is all about creating DCs that have optimized signaling through activation that is different, maturity that is different and purity that is better that what others produce. Those little tweaks you speak of are very important. Some tweaks, like the amount of time and activators used to create mature DCs that produce certain levels of TNFalpha, IL 12 and other markers of proper activation are known about generally but not the actual exact time or the exact activators other than IL-2 and CSF-1 which is protected though described in the patents and are within the list of potential activators. So you see that the science actually does matter because the recipe matters and the recipe has a right to be protected to a certain extent. Do you know the exact O2 and CO2 levels for cell differentiation and maturation or exact process for creating strongly polarized down to non polar sites on receptors or ligands? It’s all in the tweaks and NWBO has been tweaking while the world was learning about twerking. Big difference; ). Care to tell me all about what NWBO knows about macrophages that makes their platform the one to try to compete against?; ). Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
